Malcolm DeCamp

Dr. Malcolm DeCamp


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2004 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
RMRobert J McKenna
Robert J McKenna
JBJoshua O Benditt
Joshua O Benditt
Malcolm DeCampMalcolm DeCamp
Malcolm DeCamp
CDClaude Deschamps
Claude Deschamps
LKLarry Kaiser
Larry Kaiser
NGNational Emphysema Treatment Trial Research Group
National Emphysema Treatment Trial Research Group

1 May 2008 in Proceedings of the American Thoracic Society
Verified
Journal Article
Closed access
NPNamrata Patel
Namrata Patel
Malcolm DeCampMalcolm DeCamp
Malcolm DeCamp
GCGerard J. Criner
Gerard J. Criner
Lung transplantation and lung volume reduction surgery are surgical options for patients with advanced chronic obstructive pulmonary disease that is refractory to medical treatment. In this review, we discuss the differential indications for each procedure, as well as compare their risks and benefits. We also present an algorithm for selecting the most appropriate procedure for individual patients. Finally, we discuss the feasibility and role of lung transplantation after lung volume reduction surgery in the management of selected patients with chronic obstructive pulmonary disease.

1 May 2021 in Thoracic Surgery Clinics
Verified
Journal Article
Closed access
DMDaniel P. McCarthy
Daniel P. McCarthy
LTLauren J. Taylor
Lauren J. Taylor
Malcolm DeCampMalcolm DeCamp
Malcolm DeCamp

17 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MAMahmoud Abdallah
Mahmoud Abdallah
RVRick Voland
Rick Voland
Malcolm DeCampMalcolm DeCamp
Malcolm DeCamp
JFJohn C. Flickinger
John C. Flickinger
TPToni Pacioles
Toni Pacioles
JVJohn Michael Varlotto
John Michael Varlotto
Immunotherapy has made recent improvements in disease-free survival (DFS) and/or overall survival (OS) in all stages of non-small-cell lung cancer (NSCLC). Here, we review the tumor microenvironment and its immunosuppressive effects and discuss how anti-angiogenic therapies may potentiate the anti-carcinogenic effects of immunotherapy. We also review all the past literature and discuss strategies of combining anti-angiogenic therapy and immunotherapy +/− chemotherapy and hypothesize how we can use this strategy for non-small-cell lung cancer in metastatic previously untreated/previously treated settings in previously treated EGFR-mutated NSCLC for the upfront treatment of brain metastases prior to radiation therapy and for the incorporation of this strategy into stage III unresectable disease. We assert the use of anti-angiogenic therapy and immunotherapy when combined appropriately with chemotherapy and radiotherapy has the potential to increase the long-term survivals in both the stage III and metastatic setting so that we can now consider more patients to experience curative treatment.

1 March 2021 in Chest
Verified
Journal Article
Closed access
DMDaniel P. McCarthy
Daniel P. McCarthy
Malcolm DeCampMalcolm DeCamp
Malcolm DeCamp

1 January 2003 in Chest
Verified
Journal Article
Closed access
MHMarcus T. Haug
Marcus T. Haug
JCJeffrey Chapman
Jeffrey Chapman
SMSudish Murthy
Sudish Murthy
OMOmar Minai
Omar Minai
CJConstance Jennings
Constance Jennings
MAMehta Atul
Mehta Atul